动物造模,小鼠模型 zi-bio 2024-03-06 499

　　Objective: Erlotinib (trade name: Trocaine) is a new targeted drug for the treatment of non-small cell lung cancer. In recent years, it has been widely used in clinical practice, but there are many side effects, with rash being the most common and difficult for patients to accept. The aim of this study is to observe the changes in epidermis, pathology, immunohistochemistry, and other aspects of mice before and after the application of Trocaine, and to replicate an animal model of rash caused by Trocaine, providing a model for clinical topical drug treatment of rash.

　　Method: Twenty BALB/c female mice were randomly divided into four groups. The experimental group (groups II, III, and IV) was orally administered with a concentration of 10 g/L of Trokai solution at a rate of 100 mg/kg, while the control group (group I) was orally administered with an equal volume of deionized water once a day. Hair was removed from the head, neck, back, and waist of mice 24 hours before administration. After the experiment, the skin of the neck, back, and waist was cut and the changes in the naked skin, pathological sections, immunohistochemistry, and other aspects of the experimental group and control group mice were observed.

　　Result: (1) There were statistically significant differences (P<0.01 or P<0.05) among="" the="" four="" groups="" of="" mice="" in="" terms="" hair="" regeneration="" complete="" shedding="" rash="" appearance="" and="" pore="" expansion="" ki67:="" there="" was="" no="" statistically="" significant="" difference="" between="" p="">0.05).

　　Conclusion: (1) This experiment confirms the view of many researchers that the rash caused by EGFRIs is an inflammatory response; (2) This rash model is reliable, practical, and reproducible, suitable for the large-scale establishment of animal models of rash caused by EGFRIs. It can be promoted for clinical, experimental, and research purposes.